Subra Kugathasan, MD                    

Titles
Program director, Inflammatory Bowel Disease, Children's Hospital of Wisconsin; associate professor, Pediatrics, Medical College of Wisconsin.

Study interests
Biological therapies for pediatric inflammatory bowel disease, genetic epidemiology of pediatric inflammatory bowel disease.

Education
MBBS, University of Columbo, Columbo, Sri Lanka, 1985; senior house officer, registrar and senior registrar, pediatrics, University Hospitals of Wales, Cardiff, UK, 1988-1993; residency, Sinai Hospital of Baltimore, John Hopkins University School of Medicine, Baltimore, 1994; fellowship, Pediatric Gastroenterology and Nutrition, Rainbow Babies and Children's Hospital, University Hospitals of Cleveland, Case Western Reserve University School of Medicine, Cleveland, Ohio, 1997; research fellowship, Mucosal Immunology, Case Western Reserve University School of Medicine, Cleveland, Ohio, 1997.

Certifications
Pediatrics, 2002; Gastroenterology, 1997; Educational Commission for Foreign Medical Graduates, 1992.

Honors
New Initiative Award, Digestive Disease Center, Medical College of Wisconsin, 2000; Mentored Patient-oriented Research Career Development Award, National Institutes of Health (K-23 RR016111), 2001; Clinical Scholar Award, NIH, 2001; Clinical physician award, Clinical Scholarship, "Creation of a Pediatric IBD database for the State of Wisconsin," Department of Pediatrics, Children's Hospital of Wisconsin, Medical College of Wisconsin, 2002; Physician of the Year Award, Wisconsin Chapter, Crohn's and Colitis Foundation of America, 2002; Young Investigator Award for Clinical Research, North American Society for Pediatric Gastroenterology, Hepatology and Nutrition, 2002; New Initiative Award, Digestive Disease Center, Medical College of Wisconsin, 2002; Junior-Physician Investigator award, American Federation for Medical Research, 2003; Children's Hospital and Health System Foundation Research Award, 2003; Senior Investigator Research Award, Crohn's and Colitis Foundation of America, 2004.

Representative publications

• Kugathasan S, Willis J, Dahms BB, O'Riordan MA, Hupertz V, Binion DG, Boyle JT, Fiocchi C. Intrinsic Hyperreactivity of Mussel T-cells to Interleukin-2 in Pediatric Crohn's Disease. Journal of Pediatrics. 1998; 133:675-81.
• Kugathasan S, Werlin SL, Martinez A, Rivera, M, Heikenen J, Binion DG. Prolonged Duration of Response to Infliximab in Early but Not Late Pediatric Crohn's Disease. American Journal of Gastroenterology. 2000; 95:3189-3194.
• Kugathasan S, Halabi I, Telega G, Werlin SL. Pancreatitis as a Presenting Manifestation of Pediatric Crohn's Disease. Journal of Pediatric Gatroenterology Nutrition. 2002; 35:96-98.
• Kugathasan S, Levy MP, Saein K, Kim JP, Vasilopoulos S, Emmonsm J, Martinez A, Kelly KJ, Binion D. Infliximab Re-treatment in Crohn's Disease Adults and Children: Risk Factors for the Development of Delayed Severe Systemic Reaction. American Journal of Gastroenterology. 2002; 97:1408-14.
• Kugathasan S, Miranda A, Nocton J, Drolet BA, Raasch C, Binion DG. Treatment Resistant Dermatological Manifestations of Crohn's Disease in Children: Response to Infliximab Therapy. Journal of Pediatric Gatroenterology Nutrition.  2003;37:150-154.
• Kugathasan S, Judd R, Hoffmann R, Heikenen J, Telega G, Khan F, Weisdorf-Schindele S, San Pablo Jr W, Perroult J, Park R, Yaffe M, Brown C, Rivera-Bennett MT, Halabi I, Martinez A, Blank E, Werlin SL, Rudolph C, Binion DG for the Wisconsin Pediatric IBD Alliance. Epidemiologic and Clinical Characteristics of Children with Newly Diagnosed Pediatric Inflammatory Bowel Disease in Wisconsin: A Statewide Population-based Study. Journal of Pediatrics. 2003; 143:525-31.

Grants

• A Phase 2, International, Multicenter, Open Label Study of the Safety, Tolerability and Effectiveness of Maintenance Infusions of Antegren (NATALIZUMAB) in Adolescents with Moderately to Severely Active Crohn's Disease, Elan Pharmaceuticals, 2002–present, principal investigator (local).
• A Randomized, Multicenter, Open Label Study to Evaluate the Safety and Efficacy of Anti-TNF Chimeric Monoclonal Antibody.
• Mucosal T-cells in Early and Late Pediatric Crohn's Disease, National Institutes of Health, Patient-oriented Research Career Development Award K-23 RR016111, 2001-2005, principal investigator, direct funds: $662,809.
• Genotype/Phenotype Correlation in New Onset Pediatric IBD Patients, Children's Hospital and Health System Foundation Grant, 2003–2005, principal investigator, direct funds: $70,000.
• Genotype/Phenotype Correlation in New Onset Pediatric Crohn's Disease, Senior Investigator Award, Crohn's and Colitis Foundation of America, 2004-2007, principal investigator, direct funds: $230,000.
• (Infliximab, REMICADE) in Pediatric Subjects With Moderate To Severe Crohn's Disease (REACH) Centocor, 2003–present, principal investigator (local).
• ACORDIS (A Crohn's Disease Optimal Range Dosing of IMURAN study), Food and Drug Administration, 2004-present, local principal investigator (main site, Harvard Medical School).

Contact
Children's Research Institute
8701 Watertown Plank Road
Wauwatosa, WI 53226
Phone: (414) 266-3690
Fax: (414) 266-3676
E-mail: skuga@mcw.edu